Modality
Radioligand
MOA
BETi
Target
WRN
Pathway
Notch
CML
Development Pipeline
Preclinical
~Mar 2019
→ ~Jun 2020
Phase 1
~Sep 2020
→ ~Dec 2021
Phase 2
Mar 2022
→ Jun 2031
Phase 2Current
NCT04651757
1,701 pts·CML
2022-03→2031-06·Terminated
1,701 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-235.2y awayPh2 Data· CML
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Termina…
Catalysts
Ph2 Data
2031-06-23 · 5.2y away
CML
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04651757 | Phase 2 | CML | Terminated | 1701 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| BII-1564 | Biogen | Phase 2 | PSMA |